U.S. Gastrointestinal Therapeutics Market, 2025-2033
The gastrointestinal therapeutics market in the United States is expected to reach a projected revenue of US$ 15,091.7 million by 2033. A compound annual growth rate of 1.4% is expected of the United States gastrointestinal therapeutics market from 2026 to 2033.
U.S. gastrointestinal therapeutics market highlights
The U.S. gastrointestinal therapeutics market generated a revenue of USD 13,556.4 million in 2025 and is expected to reach USD 15,091.7 million by 2033.
The U.S. market is expected to grow at a CAGR of 1.4% from 2026 to 2033.
In terms of segment, branded was the largest revenue generating drug type in 2025.
Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastrointestinal therapeutics market data book summary
Market revenue in 2025
USD 13,556.4 million
Market revenue in 2033
USD 15,091.7 million
Growth rate
1.4% (CAGR from 2026 to 2033)
Largest segment
Branded
Fastest growing segment
Generics
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Branded, Generics
Key market players worldwide
AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares
Other key industry trends
In terms of revenue, U.S. accounted for 31.7% of the global gastrointestinal therapeutics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In North America, U.S. gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2033.
Mexico is the fastest growing regional market in North America and is projected to reach USD 643.6 million by 2033.
The U.S. accounted for the largest share in North America gastrointestinal therapeutics market and is anticipated to maintain its dominance during the forecast period, owing to high healthcare expenditure, rising prevalence of gastrointestinal disorders, and greater adoption of branded drugs.
Furthermore, key players in the market are extensively investing in R&D, which has resulted in numerous drug approvals in the recent years. For instance, in October 2019, Johnson & Johnson received FDA approval for its drug STELARA (ustekinumab) indicated for moderately to severely active ulcerative colitis in adult patients.
In addition, in June 2019, Allergan plc and its partner Ironwood Pharmaceuticals, Inc announced positive results from a phase IIIb clinical trial study investigating LINZESS (linaclotide) 290 mcg on multiple abdominal indications in adult patients with Irritable Bowel Syndrome with Constipation (IBS-C).
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gastrointestinal Therapeutics Market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.49% in 2025.
Horizon Databook has segmented the U.S. gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. accounted for the largest share in North America gastrointestinal therapeutics market and is anticipated to maintain its dominance during the forecast period, owing to high healthcare expenditure, rising prevalence of gastrointestinal disorders, and greater adoption of branded drugs.
Furthermore, key players in the market are extensively investing in R&D, which has resulted in numerous drug approvals in the recent years. For instance, in October 2019, Johnson & Johnson received FDA approval for its drug STELARA (ustekinumab) indicated for moderately to severely active ulcerative colitis in adult patients.
In addition, in June 2019, Allergan plc and its partner Ironwood Pharmaceuticals, Inc announced positive results from a phase IIIb clinical trial study investigating LINZESS (linaclotide) 290 mcg on multiple abdominal indications in adult patients with Irritable Bowel Syndrome with Constipation (IBS-C).
U.S. Gastrointestinal Therapeutics Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
Branded
Generics
U.S. Gastrointestinal Therapeutics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Aminosalicylates
Digestive Enzymes
Proton Pump Inhibitors
Laxatives
Anti-emetics
H2 Antagonists
Anti-diarrheals
Biologics/Biosimilar
Other Drug Classes
U.S. Gastrointestinal Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Injectables
Others Route of Administrations
U.S. Gastrointestinal Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
Crohn's disease
Ulcerative colitis
GERD
IBS
Others Applications
U.S. Gastrointestinal Therapeutics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Reasons to subscribe to gastrointestinal therapeutics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of gastrointestinal therapeutics market databook
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into U.S. gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Gastrointestinal Therapeutics Market, 2021-2033 (US$M)